Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab

Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Brain Sci
Huvudupphovsmän: Maier, Smaranda, Simu, Mihaela, Hutanu, Adina, Barcutean, Laura, Voidazan, Septimiu, Bajko, Zoltan, Motataianu, Anca, Lata, Irina, Balasa, Rodica
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692182/
https://ncbi.nlm.nih.gov/pubmed/33143271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/brainsci10110802
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk